SteQeyma公司在五个主要欧洲市场推出新的自动免疫疾病治疗。 Celltrion launches new autoimmune disease treatment SteQeyma in five major European markets.

韩国制药公司Celltrion在法国、意大利、德国、西班牙和联合王国等五个主要欧洲国家启动了SteQeyma,这是治疗自发免疫疾病的治疗方法。 South Korean pharmaceutical company Celltrion has launched SteQeyma, a treatment for autoimmune diseases, in five major European countries, including France, Italy, Germany, Spain, and the UK. 8月,欧洲联盟委员会批准了SteQeyma, SteQeyma在慢性发炎性疾病方面是一种与ustekinumab相似的生物。 Approved by the European Commission in August, SteQeyma is an ustekinumab biosimilar for chronic inflammatory diseases. 计划扩大欧洲的销售量,并最终将产品引入美国市场,目标是到2025年实现5万亿韩元(35.8亿美元)的年度销售量。 Celltrion plans to expand sales in Europe and eventually introduce the product to the US market, aiming for 5 trillion won ($3.58 billion) in annual sales by 2025.